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1. Introduction 
Foot ulceration is among the most significant complications of diabetes. It is estimated that 
15% of the diabetic patients develop ulcers at some point in their lives (Reiber, 1996). The 
therapeutic management of a diabetic patient carrying a diabetic foot ulcer (DFU) is 
currently based on: metabolic control, debridement (Brem et al., 2004), moist cures, wound 
dressing, local pressure off-loading, antimicrobial treatment of infections, and 
revascularization procedures, when indicated. More recent therapies such as topical growth 
factors (Tsang et al., 2003; Brem et al., 2004; Eldor et al., 2004; Hong et al., 2006; Viswanathan 
et al., 2006), skin substitutes (Marston et al., 2003; Veves et al., 2001), and others have shown 
efficacy in pure neuropathic, non-complicated ulcers. However, these products would still 
have to be tested in advanced lesions including those with an ischemic etiopathogenic 
component. Still 10 to 30% of the cases progress to amputation, frequently preceded by 
gangrene and infection (Lipsky, 2004). After amputation of a lower limb, the five year 
mortality rate reaches 50-60% (Reiber, 1996). Therefore, despite progress in the diagnosis 
and treatment of infection and other complications (Lipsky, 2004; Williams et al., 2004), the 
advanced DFU is still an unmet medical need. 
The local (intralesional) instillation of recombinant human epidermal growth factor (rhEGF) 
to promote granulation and healing of chronic, advanced DFU has been recently introduced 
in medical practice in some countries. This chapter will review the rationale, experimental 
background, and clinical development of such procedure.  
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2. Why can Epidermal Growth Factor (EGF) be used for the treatment of 
Diabetic Foot Ulcers (DFU)? 
Epidermal growth factor (EGF) is a 53 aminoacid polypeptide that was isolated for the first 
time by Cohen from mice submaxillary glands (Cohen, 1962). It stimulates the proliferation 
of fibroblasts, keratinocytes and vascular endothelial cells, which contribute to its scar tissue 
formation property. Its action is launched by the interaction with specific receptors located 
on the cellular membrane. The EGF receptor is a glycoprotein with an extracellular binding 
domain, a transmembrane region and a cytoplasmic portion with tyrosine kinase activity 
(Bazley & Gullick, 2005). This receptor is expressed on most human cell types including 
those which play critical roles for wound repair such as fibroblasts, endothelial cells and 
keratinocytes (undifferentiated, marginal, leading edge, hair follicles, sweat ducts and 
sebaceous glands). Only hematopoietic cell lineages lack the EGF receptor (Werner & Grose, 
2003). The rationale of the use of Epidermal Growth Factor (EGF) for the treatment of (DFU) 
is based on: 
2.1 Impairment of healing in diabetic patients, partially due to a relative deficit of 
growth factors (EGF among them) in the wound area 
Wound healing is an ancestral mechanism evolutionarily designed to ensure the structural 
and functional restoration of an injured area. The mechanism involves cellular responses 
from two major classes: (i) repair-committed cells such as fibroblasts, other mesenchymal-
derived cells, endothelial / angiogenic precursor cells and epithelial keratinocytes and (ii) 
inflammatory cells that are transiently recruited and temporarily infiltrate the wound 
(Eming et al., 2007). Under physiological conditions this process is ensued by inflammatory 
cells’ progressive apoptosis and inflammation cessation. Although in diabetic wounds the 
cells and the pro-inflammatory cytokines are the same than in non-diabetic, acute 
counterparts; inflammation is more a condition than a reaction. The perpetuation of 
neutrophils, macrophages and their related pro-inflammatory cytokines in diabetic wounds 
contribute to the onset of a pro-degradative microenvironment which results from the 
imbalance between matrix synthesis and degradation (Berlanga et al., 2008). 
Under these circumstances the local pool of growth factors (GFs) and their corresponding 
receptors turn detrimental due to a reduced transcriptional expression by the wound bed 
committed cells and/or to increased enzymatic degradation (Clark, 2008). The role of GFs 
turns more important in the context of a diabetic wound since high glucose levels and other 
associated metabolic by-products are toxic for endothelial and fibroblastic cells, which 
become arrested and senescent. In this environment the granulation tissue promoting cells 
launch a pro-apoptogenic program which eventually hinders the granulation process 
(Goren et al., 2006). The observation that diabetic wounds are enriched in proteases supports 
the premise that impaired GFs availability may act as a rate limiting factor in diabetic 
wound healing (Burrow et al., 2007), which justifies an appropriate wound bed preparation 
and a GFs replacement therapy. 
2.2 The growth stimulating, healing promoting, and cytoprotective actions of EGF, 
including angiogenesis 
The EGF family of ligands exhibit mitogenic activity upon binding to four different high-
affinity receptors: EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4. Upon 
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ligand binding, the formation of a functionally active EGFR-EGFR homodimer or EGFR-
HER2, EGFR-HER3, or EGFR-HER4 heterodimers causes the ATP-dependent 
phosphorylation of specific tyrosine residues in the EGFR intracellular domain, which 
triggers a complex program of intracellular signals to the cytoplasm and then to the nucleus 
(Citri & Yarden, 2006).  
Another biological action unleashed by the EGF-EGFR binomium is the locomotion 
stimulation of epithelial and fibroblastic cells (Barrandon & Green, 1987). This pro-
motogenic impulse induced by the EGF-EGFR complex on keratinocytes is important for re-
epithelialization. EGF can also control fibroblasts extension, attachment or detachment 
directly or indirectly via modifications of the injured tissue extracellular matrix composition 
(Maheshwari et al., 1999). 
The EGF-induced mitogenic, motogenic, and cyto-protective actions are instrumental for 
healing events that may be summarized as: (a) stimulation of productive cells migration 
toward the injured area, (b) stimulation of granulation tissue outgrowth – including 
extracellular matrix accumulation, maturation and de novo angiogenesis, (c) stimulation of 
wound contraction by myofibroblast activation and proliferation, (d) stimulation of the 
damaged area resurfacing by epithelial cells migration and proliferation (Werner & Grose, 
2003).  
EGF is also endowed with angiogenic activity thus promoting the growth of a vascular 
mesh within the wound bed. The mechanisms behind this angiogenic effect appears to be 
related to chemotaxis of endothelial cells and the enhancement of other angiogenic factors 
expression (van Cruijsen et al., 2005). This EGF-mediated neoangiogenic action is significant 
for ischemic wounds (Grazul-Bilska et al., 2003). 
2.3 The nerve restoration action of EGF in sciatic nerve section experiments, where it 
prevented distal limb ulcers and toe loss 
Several experiments demonstrated that single or repeated EGF systemic injections exerted 
cyto-protective and proliferative responses, supporting the intrinsic ability of EGF at supra-
physiological concentrations to unleash biological events required for an effective tissue 
repair (Berlanga et al., 1998a, 1999, 2001, 2002a, 2002b). 
The effect of an EGF local injection was evaluated for the first time in tissues unrelated to 
the digestive system (which at the moment was the most common experimental substrate 
- Curling’s ulcers prevention) through the perilesional injection of EGF in rats that had 
been subjected to a complete sciatic nerve section. Two independent studies demonstrated 
that the intralesional injection of EGF produced: (i) recovery of the motor nerve impulse 
conduction; (ii) axonal recovery and remyelination, and (iii) prevented or delayed the 
onset of trophic changes of the hind limb soft tissues (plantar ulcers and toe necrosis). 
These sciatic nerve experiments suggested the possibility for a pharmacological 
management of trophic ulcers derived from a neurogenic ischemia (Prats et al., 1998). This 
animal model somewhat mirrored the condition of a neurogenic diabetic lower extremity 
in which both neuropathy and angiopathy concertedly predispose to ulceration (Dyck & 
Giannini, 1996). 
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3. Why EGF has to be injected intralesionally? 
3.1 The availability of the growth factor on the surface of the wound is limited as it 
can be degraded by proteases from the biofilm that covers the lesion and/or from its 
fluid 
The need for a prolonged interaction between EGF and its receptor to achieve a significant 
granulation tissue response in controlled wounds in mice had been reported (Buckley et al., 
1985). Proteolysis exerted by the wound-derived exudate was observed incubating the 
ulcers´ material at neutral pH with a fluorescent-synthetic peptide at room temperature. 
Pre-incubation with a protease inhibitor prevented substrate’s degradation. These 
observations suggested a possible reduction of EGF bioavailability by proteases derived 
from controlled wounds (Berlanga et al., 1998b). Other studies had already established 
proteolysis of growth factors and their receptors in chronic circumstances (Mast & Schultz, 
1996; Saarialho-Kere, 1998; Trengove et al., 1999;, Medina et al., 2005). 
Furthermore, profiles of 125I-EGF in a rat full-thickness wound model, demonstrated 
tissue-bound radioactivity 2 h after the administration. Within this period, 125I-EGF 
degraded subspecies with no diffusion of the peptide to the surrounding skin were 
identified. The receptor expression was increased 2 h after wounding, followed by a slow 
decline up to 12 h below baseline. These results point out that 125I-EGF is rapidly cleared 
from the application site probably by protease-driven cleavage and receptor-mediated 
endocytosis. The mean residence time (MRT) values suggested that more than 60% of the 
amount administered could have disappeared as early as 2 hour post-administration 
(Prats et al., 2002). Previous clinical evidences of topically applied EGF had already 
rendered disappointing results possibly due to local bioavailability limitations (Falanga et 
al., 1992;, Falanga, 1992).  
3.2 Responding granulation tissue develops from the deep layers of the wound 
An immuno-histochemical characterization of biopsy cylinders from diabetic wound beds 
shed more light on the biological sustentation for the infiltrative modality. Granulation 
tissue biopsy cylinders (approximately 7 millimeters length) from neuropathic patients were 
collected and paraffin-processed for different histochemical techniques and for incubation 
with anti-EGF receptor and anti-prohibitin (PHB) antibodies. The monoclonal antibody 
against EGF receptor EGFR-pY1197 (1:250, DAKO) binds to tyrosine residue 1197 when it is 
phosphorylated, indicating downstream signaling activation. Prohibitin rabbit monoclonal 
(Abcam. EP2804Y) was diluted at 1:200. EnVision + Dual Link System-HRP was used to 
develop the reaction. Slides were hematoxylin counterstained. Pictures were obtained at 
X 40 constant magnification. The figure shows three strata along the longitudinal axis of the 
biopsy material were defined: upper, middle, and bottom. Fibroblasts populating the more 
superficial stratum expressed more prohibitin and less EGF-receptor. Prohibitin is an 
inhibitor of cell cycle progression and may therefore contribute to the onset of wound’s 
chronic phenotype. (Mishra et al., 2010; Lee et al., 2010; Dong et al. 2010). This expression 
profile became progressively inverted going through deeper cells layers (Fig. 1). Advanced 
glycation end products and elastase also appeared more intensely labeled next to the wound 
surface than in deeper cells strata (not shown). 
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Fig. 1. EGF receptor (left) and prohibitin (right) expressions along the biopsy longitudinal 
axis. 
4. Clinical development of intralesional recombinant human EGF in advanced 
DFU. Efficacy results 
A formulation of recombinant human Epidermal Growth Factor (rhEGF) for intralesional 
administration in DFU has been developed. The growth factor is purified from a 
transformed Saccharomyces cerevisiae strain and presented as a lyophilized preparation 
containing 25 or 75 µg of rhEGF per vial. The efficacy and safety of the intervention has been 
tested in five exploratory and one confirmatory randomized, double-blind, placebo control 
clinical trials (Berlanga et al., 2006; Fernandez-Montequin et al., 2007, 2009a, 2009b). A total 
of 344 patients took part in these studies (Table 1). 
This clinical development has dealt with a type of patient not usually recruited in DFU 
clinical trials. The characteristics of the patients included have been quite homogeneous 
across the trials, given essentially by (i) long-lasting Diabetes Mellitus, mostly type 2; (ii) 
median age >60 years; (iii) chronic ulcers (more than one month of evolution); (iv) deep 
ulcers (exposes cellular subcutaneous tissue or tendons, or joint capsule); (v) advanced, 
given by large size (median area always > 20 cm2), baseline infection (that had to treated 
before the use of rhEGF), necrotic tissue (that had to be removed surgically); (vi) 
approximately one half of the patients with deficient irrigation of the corresponding leg 
(ischemia). The three latter features are usually exclusion criteria in DFU clinical trials. Such 
ulcers corresponded to grades 3 or 4 of the Wagner´s classification (Armstrong et al., 
1998).These patients, which can represent 50% of the whole DFU population, lead to most of 
the amputations. 
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Patients with hemoglobin <100 g/l, uncontrolled chronic diseases, psychiatric disorders, 
malignancies, pregnant or breastfeeding, were excluded. Signed, informed consent was an 
inclusion requisite in all trials, which were approved by the corresponding Ethics 
Committees and by the National Regulatory Authority. 
Intralesional rhEGF was administered adjuvant to the conventional good wound care 
measures: metabolic control, thorough debridement of necrotic and infected tissue, pressure 
off-loading, and antimicrobials if needed. The product was dissolved in 5 ml of water for 
injection or saline and distributed evenly throughout the lesion in 5 to 10 punctures, starting 
from the cleanest zones. The needle was changed between injections in order to prevent 
infection dissemination. Treatment was given three times per week on alternate days, until 
complete granulation response or a maximum of 8 weeks. Only in trial No. 0705 treatment 
was continued until wound closure. Subjects were hospitalized during treatment in all trials 
and then followed-up, generally for one year, as outpatients. 
The main outcome variable in most of the studies was the development of granulation 
tissue, classified, according to the lesion area covered, in: (i) no response: less than 25% 
granulation; (ii) minimal response: 25 to 50%; partial response: 50 to 75%; complete 
response: more than 75% of the lesion area, that could support a skin graft to complete ulcer 
closure. A 100% granulation response was nonetheless achieved in most complete 
responders. 
In these, more advanced ulcers, granulation is a valid outcome since it is part of the healing 
process and should necessarily precede the final healing. Besides, granulation over the ulcer 
area permits skin grafting to attain final healing, so a group of patients does not reach 
complete spontaneous healing to be evaluated. Additionally, a significant correlation was 
found between granulation and healing in the confirmatory study No. 0503 (Fernandez-
Montequin et al., 2009b). Previous studies had identified partial wound closure as predictive 
of complete healing for Wagner’s grade 1 or 2 DFU (Sheehan et al., 2006), and other ulcers 
(van Rijswijk & Polansky, 1994;, Kantor & Margolis, 2000), but this was the first report of an 
early surrogate endpoint in Wagner’s grade 3 or 4 DFU. 
4.1 Pilot, exploratory trial in 29 patients who were bound to amputation 
Patients bore advanced DFU, Wagner´s grade 3 (10 cases) or 4 (19 cases); 23 of them were 
ischemic and had no other therapeutic alternative. Some granulation response was obtained in 
25 cases (86%) and the complete response and lesion closure in 17 (59%; one of them through 
skin graft), thus preventing amputation. Recurrence appeared in only one patient after a one-
year follow-up (Berlanga et al., 2006). An immuno-histochemical study suggested that TGF β 
could be the main effector mediating the EGF-stimulated granulation process. Biopsies taken 
from neuropathic and ischemic patients showed the stimulation of granulation tissue growth 
and organization as well as the formation of new blood vessels after the treatment with rhEGF, 
illustrating its angiogenic effect (Figure 2 in Berlanga et al., 2006). 
4.2 Dose exploratory trial 
A controlled, double-blinded, randomized and multicenter clinical trial was later carried out 
in five institutions to explore a possible dose-dependent response (Fernandez-Montequín et 
al., 2007). 
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Forty-one patients bearing Wagner’s grade 3 and 4 lesions were included. They were 
randomly distributed in two groups receiving rhEGF at 75 μg or 25 μg. A tendency to 
better results with the higher dose was observed: higher granulation response rate and 
faster, but groups behaved similar concerning wound closure during follow-up. Only one 
patient relapsed in the follow-up. In some of the cases wound contraction could be 
evidenced as part of the healing process (Figure 2). This property is usually abolished in 
diabetic patients. 
 
Fig. 2. Evidence of granulation and healing in two patients from study No. 0202. Upper line: 
65 years-old female. An ischemic 38 cm2 transmetatarsal amputation base was treated with 
rhEGF. A: before the beginning of treatment; B: after 5 weeks (15 infiltrations) complete 
granulation was achieved; C: healing occurred at 29 weeks. Lower line: 46 years-old female 
with ischemic and infected DFU. After toe disarticulation and antibiotics, she was treated 
with rhEGF. D: before treatment; E: after 4 weeks (12 infiltrations) complete granulation was 
achieved; F: Healing was reported at 17 weeks. Wound contraction is evident as part of the 
healing mechanism.  (Picture taken from Fernandez-Montequin et al. 2007) 
4.3 Series of 12 patients treated with the 75 µg dose (not published) 
The results obtained agree with those obtained in previous trials. Most of the patients 
responded satisfactorily. The observed total response rate was 75%. Major amputations 
were carried out in 3 patients (25%), all ischemic, associated to the occurrence of local 
infection in two of them. 
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4.4 Monitoring of patients treated after initial conditional marketing approval of the 
product (not published) 
A multicenter, non-controlled, phase IV-type study was based on the reports of all treated 
cases after an initial conditional marketing approval in Cuba. The rhEGF began to be used 
throughout the country and was administered at 25 μg, three times per week until complete 
granulation or up to 8 weeks. Results were consistent with the previous ones. Relapse was 
present in only one patient after one year follow-up. 
4.5 Series of patients treated with 75 µg up to wound closure 
Twenty patients were included and treated with intralesional rhEGF, three times per week, 
until the lesion closure was attained (Fernandez-Montequín et al, 2009a). According to 
Wagner’s classification, 16 patients (80%) were grade 3 and 4 (20%) were grade 4. The mean 
initial area of the lesions was 16.3 ± 21.3 cm2. There was evidence of ischemia in 5 patients 
(25%), whose limb occlusion pattern was at a distal level. A complete granulation response 
was obtained in all cases, complete lesion closure in 17 (85%) and none of them required 
amputation. The mean healing time was only 6 weeks. There was one wound recurrence 6 
months after healing. This study indicated that rhEGF can be used after total granulation 
until the lesion is completely closed or until its area is significantly reduced (≤ 1 cm2). 
4.6 Multicenter, double-blind, placebo-controlled confirmatory trial 
A confirmatory, multicenter, randomized, double-blind trial was carried out (Fernandez-
Montequín et al, 2009b). Besides, it was compared to placebo. The latter was required to 
provide unquestionable evidence on the efficacy of intralesional rhEGF administration; to 
rule out that the results obtained were explained by good wound care that improves under 
clinical trial settings or due to the endogenous local production of growth factors induced 
by the debridement and injection procedures. 
The study was carried out at 20 institutions in all Cuban provinces. The treatment consisted 
of three applications of 75 μg EGF, 25 μg, or placebo for 8 weeks or until complete 
granulation, adjuvant to general good wound care. 
Due to ethical reasons, to avoid giving placebo to a non-responder, if less than 25% of the 
ulcer area was covered by granulation tissue after two weeks of treatment, the patient´s 
code was opened and the patient switched to 25 μg rhEGF, when on the placebo, or 75 μg, 
when on 25 μg. The main evaluation variable was the existence of at least a partial response 
(50% of the lesion area covered by granulation tissue) after two weeks of treatment, since 
this was the period when all patients were randomized and double-blinded in their original 
treatment groups. The hypothesis of the trial was to obtain at least 30% advantage in the 
proportion of individuals with an objective response at that moment in the groups treated 
with rhEGF as compared to the placebo. The secondary variables taken into account were 
the existence of a complete granulation response at the end of treatment, the time to 
complete response, lesion closure during the 12 months follow-up, time to closure, the 
occurrence of relapses and the need for amputation. Safety was evaluated by adverse events 
monitoring and laboratory variables. All the analyses were made under the principle of 
“intention to treat”. 
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One hundred and forty-nine patients were included. Groups were equivalent in regard to 
demographic and baseline variables. Both dosage groups fulfilled the study hypothesis of 
more than 30% advantage over the placebo group, in the proportion of patients with more 
than 50% of the lesion area covered by granulation tissue. Differences (and their 95% CI) 
with respect to the placebo are shown in Table 1. Superiority in relative terms (OR) was 7.5 
(2.9 – 18.9) and 3.7 (1.6 – 8.7) for the high and the low doses, respectively. 
After eight weeks, the proportion of patients with complete granulation response was 
significantly higher only for the 75 μg treatment compared to placebo. The benefits of the 
treatment were more evident for the neuroinfectious origin cases than in those with an 
ischemic component. The time required for a complete response was 3 weeks for each group 
receiving EGF and 5 weeks for the placebo. This difference was statistically significant for 
both dosage levels. 
The evaluation of the complete closure of the ulcers was performed during the 12-month 
follow-up. The statistical multivariate analysis of lesion healing showed that the factors that 
favored ulcer closure were rhEGF 75 μg vs. control (OR: 3.6; 95% CI: 1.4 – 9.5), the “pure” 
neuropathic vs. ischemic character (5.5; 2.3 – 13.5), and an initial smaller ulcer size (0.98; 0.96 
– 0.99). Relapses only occurred in the placebo group. Although amputations were too few to 
support any statistical analysis, it is remarkable that there was only one amputation among 
the neuropathic patients treated with rhEGF at any of the dosages, while 15% of the 
neuropathic cases required amputation in the placebo group. There was only one failure 
after two weeks in the group receiving rhEGF at 75 μg. 
This trial confirmed the efficacy of intralesional rhEGF in advanced DFUs. The results were 
better in the group using the high dose, although both dosage levels fulfilled the efficacy 
hypothesis for the main variable (partial granulation response after two weeks). Besides, 
only the high dose showed significant differences compared to the control group for some 
secondary variables, suggesting a dose-dependent effect. This is particularly important for 
patients with ischemia, which is an adverse condition for granulation and healing 
 
Study details Variables evaluated Treatment 
75 µg 
rhEGF 
25 µg 
rhEGF 
Placebo 
Code: 0102 
Pilot; exploratory; grades 3 
and 4 ulcers, ischemic and 
neuropathic; high risk of 
amputation 
Treatment: 25 µg, 3 times 
per week until complete 
granulation or 8 weeks 
maximum. Follow-up for 
one year. 
Ref: Berlanga et al. 2006 
N 29 
Complete granulation at the 
end of treatment   
17 (59%) 
 
Wound closure during 
follow-up  
17 (59%) 
 
Time to complete 
granulation in weeks (mean 
± SD) 
 
4.7 ± 1.5 
 
Time to wound closure in 
weeks (95% CI)  
7 (1; 13) 
 
Amputations  12 (41%)  
Code: 0202 
Dose exploratory study; 
grades 3 and 4 ulcers, 
N 23 18 
Complete granulation at the 
end of treatment 
19 (83%) 11 (61%) 
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Study details Variables evaluated Treatment 
75 µg 
rhEGF 
25 µg 
rhEGF 
Placebo 
ischemic and neuropathic; 
Design: multicenter, 
randomized, double blind.
Treatment: 25 µg or 75 µg, 
3 times per week until 
complete granulation or 8 
weeks maximum. Follow-
up for one year 
Ref.: Fernandez et al., 2007
Wound closure during 
follow-up 
13 (57%) 9 (50%) 
 
Time to complete 
granulation in weeks (mean 
± SD) 
3.8 ± 2.2 4.9 ± 2.2 
 
Time to wound closure in 
weeks (95% CI) 
21 (17; 24) 20 (16; 23) 
 
Amputations 
8 (35%) 6 (33%) 
 
Code: 0504 
Lineal, patient series. 
Ulcers: grade 4, ischemic 
and  neuropathic;  
Treatment: 75 µg, 3 times 
per week until granulation 
or 8 weeks maximum 
Not published 
N 12 
Complete granulation at the 
end of treatment 
9 (75%) 
  
Amputations 
3 (25%) 
  
Code: 0604;  
Lineal, phase IV – type 
study after conditional 
approval; Ulcers: grade 3 
and 4, ischemic and 
neuropathic. 
Treatment: 25 µg, 3 times 
per week until granulation 
or 8 weeks maximum. 
3- year follow-up. 
Not published 
N 93
Complete granulation at the 
end of treatment  
78 (84%) 
 
Wound closure during 
follow-up  (16 patients lost)  
46 (49%) 
 
Time to wound closure in 
weeks (95% CI)  
10 (9; 11) 
 
Amputations
 
26 (28%) 
 
Code: 0705;  
Lineal, patient series. 
Ulcers: grade 3 and 4, 
ischemic and neuropathic; 
Treatment: 75 µg, 3 times 
per week until healing or 
12 weeks maximum  
Ref.: Fernandez et al., 
2009a 
N 20
Complete granulation at the 
end of treatment
20 (100%)
 
Wound closure 17 (85%)
Time to complete 
granulation in weeks (mean 
± SD)
3.4 ± 0.5 
  
Time to wound closure in 
weeks (95% CI)
6.3 (4; 9) 
 
Amputations 0  
Code: 0503 
Confirmatory multicenter, 
randomized, double blind, 
placebo-controlled trial; 20 
sites;  
Ulcers: grade 3 and 4, 
N 53 48 48 
No response at 2 weeks; 
code opened 
1 (2%) 5 (10%) 8 (17%) 
≥50% granulation at 2 weeks 
(95% CI  of the difference 
with placebo) 
44 (83%)
(24; 63) 
34 (71%) 
(10; 52) 
19 (40%) 
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Study details Variables evaluated Treatment 
75 µg 
rhEGF 
25 µg 
rhEGF 
Placebo 
ischemic and neuropathic; 
Treatment: 25 µg, 75 µg, or 
placebo 3 times per week 
until complete granulation 
or 8 weeks maximum. 
Follow-up for one year. 
If no response at 2 weeks, 
code opened and if 
placebo, switched to 25 µg; 
if 25 µg, switched to 75 µg.
Ref.: Fernandez et al., 
2009b 
Complete granulation at the 
end of treatment (95% CI  of 
the difference with placebo) 
46 (87%) 
(6; 39) 
35 (73%) 
(-8; 29) 
28 (58%) 
 
Time to complete 
granulation in weeks (95% 
CI) 
3 (2.6; 3.4) 3 (2.2; 3.8) 5 (3.4; 6.6) 
Wound closure during 
follow-up  
(95% CI of the difference 
with placebo) 
41 (77%)
(1; 41) 
25 
(52%) 
27 
(56%) 
Time to wound closure in 
weeks (95% CI) 
15.7 (10; 
22) 
17.3 (11; 
24) 
21.4 (8; 35) 
Amputations 7 (13%) 10 (21%) 12 (25%) 
Pooled analysis N 108 188 48 
Complete granulation at the 
end of treatment 
94 (87%) 141 (75%) 28 (58%) 
Wound closure during 
follow-up 
71/96 
(74%) 
97 (52%) 27 (56%) 
Time to wound closure in 
weeks (95% CI) 
14  (12; 16) 12 (10; 14) 21.4 (8; 35) 
Amputations 18 (17%) 54 (29%) 12 (25%) 
Table 1. Summary of characteristics and results of clinical trials with rhEGF in DFU. SD: 
standard deviation; CI: confidence interval  
4.7 Long-term follow-up of the patients included in all clinical trials 
Overall, 323 individuals were enrolled in clinical trials since 2001 (one patient took part in 
studies 0604 and 0503). They were visited in 2010 looking for information on survival, 
recurrences, new foot ulcers, amputations, adverse events and co-morbidities, including 
neoplasia. The median follow-up period was 3 years (maximum, 8 years). The results are 
summarized in Table 2. Patients from study No. 0705 were not followed-up since they live 
abroad. Patients from study No. 0503 were considered “per protocol” for this evaluation, 
since some had switched treatment at 2 weeks. 
No evidence was gathered indicating that intralesional rhEGF administration could 
stimulate cancer growth. Two patients had developed malignancies: one who had received 
rhEGF at 25 µg; the other was from the placebo group of the phase III trial.  
Thirty nine percent of the patients had deceased. The more frequent causes of death were 
heart infarct, chronic renal failure, and stroke. Median survival was longer in patients that 
had attained ulcer-healing: 5.7 ± 0.8 years vs. 4.2 ± 0.7 years in those who did not heal 
(p=0.004). 
The frequency of relapses at any moment was significantly lower (p<0.001) in patients that 
received rhEGF (10% and 4% for the 75 µg and 25 µg doses, respectively) as compared to the 
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control group of the confirmatory, No. 0503, trial (23%). This effect was obtained for both 
neuropathic and ischemic patients. On the contrary, no effect was seen on the appearance of 
DFU on other locations (mainly on the contralateral limb). The rates were 26%, 24%, and 
32% for patients treated with 75 µg rhEGF, 25 µg, and placebo, respectively. It seems as if the 
tissue keeps a sort of “memory” of the treatment received, which is not transferable to non-
treated zones. Molecular and immunohistochemistry studies are in course to elucidate these 
mechanisms. 
 
Trial Dose Enrolled Followed-up Recurrences New ulcers Amputations Cancer 
0102 25 µg 29 29 1 7 13 
0202 
25 µg 18 18 0 6 9 
75 µg 23 22 1 11 12 
0504 75 µg 12 11 1 0 4 
0604 25 µg 93 66 3 20 29 1 
0503 
25 µg 49 43 1 12 15 
75 µg 57 51 5 11 16 
Placebo 43 42 8 13 15 1 
Table 2. Long term follow-up of patients from all clinical trials with rhEGF in DFU 
Amputations were necessary in 114 patients at some moment after rhEGF treatment. The 
amputation rates were 35% for both rhEGF dose levels, the same as for the control group of 
the confirmatory trial. However, if only neuropathic and mild ischemic patients are taken 
into account amputations were less among patients treated with rhEGF 75 µg (14%) or 25 µg 
(20%) than among those who only received the good standard care (33%). Thus, severe and 
critic ischemia is still an adverse condition, difficult to overcome. Probably rhEGF should be 
used in those cases after appropriate revascularization procedures that improve tissue blood 
supply. 
4.8 Consistency of the efficacy results from the different trials 
Efficacy measurements across the different studies, summarized in Table 1, are consistent. 
More than 80% granulation was obtained globally for both dose levels used. They are much 
better than what was obtained for a group of patients that received only standard care (the 
placebo group of study No. 0503). The fact than only one study had a control group is a 
limitation to this comparison, but there is homogeneity among the different studies with 
respect to the results obtained and the 95% confidence interval of the result in the placebo 
group falls below those of the treated groups. There seems to be a dose-dependent effect, 
since results were always better for the higher dose. Subgroup analyses, limited by the fact 
that they were not previewed in the protocols, suggest that the difference between doses is 
given by patients with more complicated ulcers (larger, with more severe ischemia). 
Results on healing are clinically relevant as well, for the 75 µg dose. Treatment-dependency 
was also found for complete closure, despite being reached during follow-up, as 
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outpatients, only under general wound care measures (except for study No. 0705, where 
treatment was continued until healing). This apparent “EGF-memory” effect on wound 
closure can be explained by the granulation tissue stimulation, which was predictive of 
closure. Granulation can also reduce the probability of infection progression, since the fresh 
tissue is better prepared to “fight” against invading micro-organisms and better irrigation 
can increase the local bioavailability of systemic antibiotic treatment. As mentioned above, 
some persistent action of rhEGF treatment should take place, leading to less relapses as well. 
Time-to-closure was also shortened in approximately 4 weeks, which is a clinically 
significant feature. 
With respect to amputations, the number of events has been very small in each study in 
order to make a proper statistical analysis. For that reason this outcome has been secondary 
in all trials. The pooled analysis after long-term follow-up, mentioned above is interesting 
for the 75 µg dose. 
5. Overview of safety 
Since all trials included very similar populations and the same therapeutic schedule (only 
the dose varied), a pooled analysis was done. Intralesional rhEGF was well tolerated. About 
half of the included patients (58.5%) reported some adverse event. Those occurring in more 
than 1% of the patients are summarized in Table 3. Pain and burning sensation at the 
administration site were the most frequent. A dose-effect relation associated to the 
appearance of shivering and chills was systematically obtained in all trials that used both 
doses and in the pooled analysis. 
Concerning intensity, the adverse events reported were 65.6 % mild, 28.6% moderate, and 
only 3.7% severe. Serious adverse events were reported in 13% of the patients from the 
clinical studies. Local infection was the more frequent serious adverse event. It caused 
hospitalization and/or amputation. It was the adverse event that most frequently lead to 
treatment interruption. It is difficult to establish a causal relationship between its 
appearance and rhEGF administration since this event is also a frequent complication of 
Wagner´s grade 3 and 4 DFU and a significant risk factor for amputation. It has been 
reported that lower extremities infection is the most frequent reason for the hospitalization 
of patients with diabetes (Edmonds & Foster, 2004). Likewise, it appeared in the placebo 
group of the controlled study 0503. Some of the factors that leave patients predisposed to 
the progress of local infection include the presence of an entryway for bacteria and the fact 
that the immune response of diabetic patients is often compromised. 
The analysis of the relationship of adverse events with demographic or baseline 
characteristics only yielded significant results for the age and ulcer etiopathogeny. A 
multivariate logistic regression model yield a significant more frequent appearance of any 
adverse event in patients ≥ 65 years old vs. younger (OR: 1.86; 95% CI: 1.09 – 3.15), and less 
frequent if the ulcer was neuropathic (OR: 0.25; 95% CI: 0.14 – 0.45). Local infection 
appeared significantly more frequently in patients with Diabetes type II than in type I: 
45/222 (16.9%) vs. 2/62 (3.1%). 
Three of the patients in the clinical trials died: one with placebo and one with each of the 
doses. Other 8 deaths occurred during follow-up (up to one year). None of the deaths can be 
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considered as related to treatment but to the underlying diabetes and/or the age of the 
patients. The death causes were: acute myocardial infarct (4), bronchopneumonia (2), 
mesenteric thrombosis, acute renal failure, acute pulmonary edema, and infection. At the 
time of follow-up, 12 months after the conclusion of the treatment, no long term adverse 
effects related to the product were reported.  
 
Adverse events 
75 µg  
N=116 
25 µg  
N=181 
Placebo  
N=48 
N % N % N % 
Pain at the administration site 21 18.1% 52 28.7% 20 41.7% 
Burning sensation at the administration site 26 22.4% 25 13.8% 14 29.2% 
Shivering 34 29.3% 18 9.9% 2 4.2% 
Local infection 20 17.2% 18 9.9% 8 16.7% 
Chills 30 25.9% 15 8.3% 1 2.1% 
Fever 9 7.8% 18 9.9% 6 12.5% 
Anemia 5 4.3% 5 2.8% 5 10.4% 
Vomiting 7 6.0% 4 2.2% 1 2.1% 
Pain on the lesion 9 7.8% 2 1.1% 0 
Nauseas 5 4.3% 3 1.7% 2 4.2% 
Chest pain 3 2.6% 4 2.2% 0 
Table 3. Frequency of patients with each adverse event in Clinical Trials. Events that 
appeared in more than 1% of the patients (pooled). 
The presence of anti-EGF autoantibodies has not been considered detrimental for adult 
animals (Raaberg et al., 1995a, 1995b) or in the healing process (Casaco et al., 2004). 
Nevertheless, immunogenicity of rhEGF was evaluated in three studies since, as a 
recombinant protein, it could exert antibody production and this is an important safety issue 
for all agencies. Anti-EGF antibodies were detected in some patients (4 in study 0202 and 5 
in study 0503). Some other patients had these antibodies naturally, before treatment. All the 
titers found were very low and there was no clear relationship with efficacy or safety results. 
The adverse event profile from the first report of the postmarketing pharmacovigilance in 
Cuba (from 1851 patients) is very similar to that from clinical trials. The most frequent 
events are shivering, pain and burning sensation at the administration site, and chills. Local 
infection is less frequent, but the most frequent among the serious events found (manuscript 
in preparation). 
A particular concern on the therapeutic use of growth factors is the possibility of 
development or stimulation of a pre-existing malignancy in the patients. The concern is 
justified by the growth stimulating property of these active principles. Practically, anti-
growth factor therapy is approved or extensively experimented for several neoplasia 
(Gonzalez et al., 2011; Caraglia et al., 2006;  Geva et al., 2010). Additionally an increase in 
any-site cancer incidence was observed in DFU patients treated with platelet-derived-
growth factor (PDGF; becaplermin), which generated a warning from regulatory agencies 
(FDA-USA, 2008).  
EGF is not an exception to this concern. In fact, the presence or history of neoplasia has been 
an exclusion criteria in all clinical trials with intralesional rhEGF and is a precaution for the 
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use of the procedure in medical practice. However, there are several theoretical and 
experimental considerations that do not support the idea that EGF treatment, at the doses 
and schedules used, could stimulate any tumor growth. These aspects are thoroughly 
discussed by Berlanga et al., 2009. Briefly: 
EGF, although growth stimulating and thus a possible tumor promoter, does not induce 
malignant transformation. 
EGF stimulation of cell lines and tumor grafts growth is not a consistent result. There are 
cases of growth inhibition by exogenously administered EGF. (Knowles et al., 1985; Barnes, 
1982) 
EGF overexpression in transgenic animals not always lead to increase in tumor development 
(Chan & Wing-Chuen, 2000). 
No increase in tumors in patients treated with topical EGF for burns, in a controlled trial 
done in Cuba in 1993-94. These patients were visited in 2008 – 2009 and their incidence of 
cancer was not above that expected for that age group in Cuba for that long period of time 
(not published result, reported by Berlanga et al., 2009) 
The pharmacokinetics study in DFU patients showed short residence in blood of 
intralesionally administered rhEGF. After 2 hours all EGF was cleared and no accumulation 
was detected after repeated injections (not published result; manuscript in preparation). 
These data are inconsistent with long-term systemic actions. 
Treatments with rhEGF are short-term: not more than 8-12 weeks, contrary to a tumor 
promoting action that would require a longer exposure. 
Lack of treatment-related cancer development in the long-term follow up of patients from 
clinical trials with rhEGF (mentioned above). This argument is nonetheless still weak since 
the result comes from few individuals. 
6. Benefit-risk analysis 
The clinical studies in patients with advanced DFU (Wagner´s grade 3 or 4, median size >20 
cm2, ischemic not excluded) have shown that intralesionally injected rhEGF, adjuvant to 
standard good wound care, has the potential to promote granulation, complete wound 
healing, even in subjects unresponsive to other treatments, faster than subjects treated with 
standard good wound care alone. The relapse rate is reduced as well. The procedure has the 
potential to reduce amputation rates, particularly in neuropathic or mild ischemic patients, 
with a considerable personal and public health improvement. 
Potential risks of the use of intralesional rhEGF in DFU can be evaluated by the safety 
profile obtained from the clinical trials and the possibility of cancer stimulation, discussed 
above. No particular treatment-related serious adverse event was observed. All can be 
explained by the underlying disease. No increase in cardiovascular, respiratory or renal 
complications was reported. Adverse events attributed to treatment have been generally 
limited to shivering, chills, and injection site pain. These have been mild and self-limiting. 
No increase in cancer development in treated patients has been observed. Local infection 
progression is the more frequent serious adverse event. Since the injection procedure can 
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potentially contribute to infection spreading, caution is recommended in this sense. Clinical 
signs of infection should be cleared before treatment with rhEGF. 
This benefit-risk balance seems quite favorable. This was also suggested by the analysis 
done using a Bayesian approach (Spiegelhalter et al., 2004) comparing the probability of 
benefit (given by complete healing) with the probability of risk (given by the occurrence of 
serious adverse events, including amputation), taking into account data from all clinical 
trials. These results are shown in Fig. 3.  
Assuming that there are two hypotheses H1 (benefit, given by ulcer healing) and H2 (risk, 
given by the occurrence of serious adverse events or amputation) proposed for the patients 
outcome data set and under Hk the data are related to the parameter vector ψk by a 
distribution with probability density ݌ሺܺ│ψ௞,	ܪ௞ሻ		. Given the prior probabilities p(benefit) 
and p(risk) = 1 – p(benefit), the data produce the posterior probabilities ݌ሺܾ݂݁݊݁݅ݐ│ܺሻ and ݌ሺݎ݅ݏ݇|ܺሻ = 1 − ݌ሺܾ݂݁݊݁݅ݐ|ܺሻ.  
The Bayes Factor (Bbr) is then: 
  )risk|p(x
)benefit|p(x
Bbr 
 
representing a summary of the evidence provided by the data in favor of benefit, as opposed 
to risk. A value larger than 1 means a favorable benefit-risk ratio.  
 
Fig. 3. Benefit and risk probability distributions of the outcome of DFU patients treated with 
intralesional rhEGF.  
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The results shown are:  
Upper graph: placebo (study No. 0503): Bbr= 1.69; difference between the probabilities: 23% 
(95% CI: 11% – 36%). 
Middle graph: treatment with 25 µg rhEGF; Bbr= 1.92; difference between probabilities: 26% 
(95% CI: 13% – 40%). 
Lower graph: treatment with 75 µg rhEGF. Bbr= 3.36; difference between probabilities: 51% 
(95% CI: 40% – 63%). 
In all cases the differences between benefit and risk probabilities favor the former; the Bayes 
factors and differences are larger for the rhEGF treated groups than for the controls. The 
balance of the higher dose is much favorable. 
7. Conclusion 
The intralesional administration of rhEGF offers a new alternative for the treatment of 
advanced DFU, reluctant to other treatments, which frequently lead to a lower limb 
amputation. Further extension of the procedure should yield impact data 
(pharmacoeconomic, limb salvage). 
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